US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BlossomHill Therapeutics

26.25

+4.0818.40%

Post-market: 26.760.5100+1.94%17:30 EDT

Volume:319.78K

Turnover:8.16M

Market Cap:804.40M

PE:-10.74

High:27.11

Open:22.34

Low:22.01

Close:22.17

52wk High:27.11

52wk Low:15.25

Shares:30.64M

Float Shares:9.38M

Volume Ratio:1.89

T/O Rate:3.41%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.4440

EPS(LYR):-24.8342

ROE:--

ROA:--

PB:-5.29

PE(LYR):-1.06

Loading ...

Overview Company News Filings

BlossomHill: Buy Rating Reiterated as BH-30643 Data Strengthen Case for C797S-Focused Path; $32 Price Target Maintained

BlossomHill updates BH-30643 lung cancer trial results

BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial

MT Newswires Live

BlossomHill Therapeutics announces updated SOLARA trial data

Blossomhill Therapeutics - to Initiate Global Phase 2 Study for Egfr C797s-Positive Nsclc in Q1 2027

THOMSON REUTERS

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target

MT Newswires Live

BlossomHill Therapeutics to Present Updated Phase 1/2 Solara Trial Data on BH-30643 in EGFR-Mutant NSCLC at WCLC 2026

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

BlossomHill Therapeutics Price Target Announced at $35.00/Share by HC Wainwright & Co.

BlossomHill Therapeutics initiated with an Outperform at LifeSci Capital

BlossomHill Therapeutics initiated with a Buy at Guggenheim

Blossomhill Therapeutics, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $35

THOMSON REUTERS

BlossomHill Therapeutics initiated with an Overweight at JPMorgan

U.S. Research Roundup-Autodesk, Hubspot, Oracle

Blossomhill Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Target Price $28

THOMSON REUTERS

Sector Update: Healthcare Stocks Flat to Higher Premarket Tuesday

MT Newswires Live

BlossomHill Says BH-30643 Gets FDA Fast Track Designation in Non-Small Cell Lung Cancer

MT Newswires Live

BlossomHill Therapeutics receives fast track designation for BH-30643 from FDA

Blossomhill Therapeutics Announces FDA Fast Track Designation for Bh-30643, a Macrocyclic Omni-Egfr™ Inhibitor for the Treatment of Advanced Egfr C797s-Positive Nsclc

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/BLSM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BLSM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BLSM\",,,,,undefined,":{"symbol":"BLSM","market":"US","secType":"STK","nameCN":"BlossomHill Therapeutics","latestPrice":26.25,"timestamp":1789588800000,"preClose":22.17,"halted":0,"volume":319780,"hourTrading":{"tag":"盘后","latestPrice":26.76,"preClose":26.25,"latestTime":"17:30 EDT","volume":7818,"amount":205250.47280400002,"timestamp":1789594236451,"change":0.51,"changeRate":0.019429,"amplitude":0.030095},"delay":0,"changeRate":0.18403247631935038,"floatShares":9375000,"shares":30643700,"eps":-2.444,"marketStatus":"Post-Mkt","change":4.08,"latestTime":"09-16 17:41:03 EDT","open":22.34,"high":27.1099,"low":22.01,"amount":8155521.381639999,"amplitude":0.230036,"askPrice":26.76,"askSize":25,"bidPrice":26.25,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.444,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"listingDate":1786075200000,"exchange":"NASDAQ","adjPreClose":22.17,"preHourTrading":{"tag":"盘前","latestPrice":20.0003,"preClose":22.17,"latestTime":"07:57 EDT","volume":36,"amount":720.0108,"timestamp":1789559857556,"change":-2.1697,"changeRate":-0.097866,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":26.76,"preClose":26.25,"latestTime":"17:30 EDT","volume":7818,"amount":205250.47280400002,"timestamp":1789594236451,"change":0.51,"changeRate":0.019429,"amplitude":0.030095},"volumeRatio":1.886982},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BLSM\",,,,,undefined,":{"symbol":"BLSM","floatShares":9375000,"roa":"--","roe":"--","lyrEps":-24.834182,"volumeRatio":1.886982,"shares":30643700,"dividePrice":0,"high":27.1099,"amplitude":0.230036,"preClose":22.17,"low":22.01,"week52Low":15.25,"pbRate":"-5.29","week52High":27.1099,"institutionHeld":0,"latestPrice":26.25,"committee":-0.923077,"eps":-2.444,"divideRate":0,"volume":319780,"delay":0,"ttmEps":-2.444,"open":22.34,"prevYearClose":16,"prevWeekClose":20.86,"prevMonthClose":18.3,"prevQuarterClose":16,"fiveDayClose":22,"twentyDayClose":16.1,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BLSM\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BLSM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BLSM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1788926400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BLSM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BLSM","date":"2026-09-15","current":-10.740589,"percent":0.111111,"low":-9.884773,"twenty":-8.847584,"median":-7.505185,"eighty":-6.922359,"high":-2.788792,"avg":-7.707014,"sd":1.365212,"marketCap":666193168},"quantilePoints":[{"date":"2026-08-07","current":-6.897356,"twenty":-6.075643,"median":-4.843074,"eighty":-3.610505,"marketCap":490298560},{"date":"2026-08-14","current":-7.048236,"twenty":-7.038752,"median":-6.897356,"eighty":-6.893907,"marketCap":501023841},{"date":"2026-08-21","current":-6.811139,"twenty":-7.038752,"median":-6.955553,"eighty":-6.893907,"marketCap":484169828},{"date":"2026-08-28","current":-8.535478,"twenty":-7.10945,"median":-6.974951,"eighty":-6.897356,"marketCap":606744468},{"date":"2026-09-04","current":-8.630317,"twenty":-8.140605,"median":-7.054702,"eighty":-6.899943,"marketCap":613486073},{"date":"2026-09-11","current":-9.272633,"twenty":-8.535478,"median":-7.091344,"eighty":-6.910289,"marketCap":659145126},{"date":"2026-09-15","current":-9.371783,"twenty":-8.847584,"median":-7.505185,"eighty":-6.922359,"marketCap":666193168}],"updateTime":1789594863734},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BLSM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667462944","title":"BlossomHill: Buy Rating Reiterated as BH-30643 Data Strengthen Case for C797S-Focused Path; $32 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2667462944","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667462944?lang=en_us&edition=fundamental","pubTime":"2026-09-16 01:35","pubTimestamp":1789493756,"startTime":"0","endTime":"0","summary":"In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on BlossomHill Therapeutics, Inc., with a price target of $32....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/blossomhill-buy-rating-reiterated-as-bh-30643-data-strengthen-case-for-c797s-focused-path-32-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/blossomhill-buy-rating-reiterated-as-bh-30643-data-strengthen-case-for-c797s-focused-path-32-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667664478","title":"BlossomHill updates BH-30643 lung cancer trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2667664478","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667664478?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:57","pubTimestamp":1789473452,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics, Inc. ( ($BLSM) ) has issued an announcement. On September 15, 2026, BlossomHill Therapeutics reported updated results fro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/blossomhill-updates-bh-30643-lung-cancer-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/blossomhill-updates-bh-30643-lung-cancer-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667443426","title":"BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667443426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667443426?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:42","pubTimestamp":1789472523,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics  said Tuesday that updated data from the phase 1/2 SOLARA trial of BH-30643 showed a 45% objective response rate and an 88% disease control rate in patients with EGFR C797S-positive non-small cell lung cancer following prior EGFR inhibitor treatment.Among 40 patients, 18 achieved a confirmed or ongoing unconfirmed partial response, while 25 remained on treatment at a median follow-up of 6.9 months, the company said.Among 174 patients treated at expansion doses of 40 mg, 50 mg or 60 mg twice daily, treatment-related dose reductions and discontinuations occurred in 9% and 3% of patients, respectively, BlossomHill said.BlossomHill plans to initiate a global phase 2 study targeting EGFR C797S-positive NSCLC in Q1 2027.Shares of the company were 6.7% higher in Tuesday premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667864112","title":"BlossomHill Therapeutics announces updated SOLARA trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2667864112","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667864112?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:10","pubTimestamp":1789470625,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics (BLSM) announced updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancerm or NSCLC,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-announces-updated-solara-trial-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-announces-updated-solara-trial-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667641885","title":"Blossomhill Therapeutics - to Initiate Global Phase 2 Study for Egfr C797s-Positive Nsclc in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667641885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667641885?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:03","pubTimestamp":1789470205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nFWN4570C8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667141644","title":"BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667141644","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667141644?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:00","pubTimestamp":1789470000,"startTime":"0","endTime":"0","summary":"45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat popul","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/15/3361888/0/en/blossomhill-therapeutics-presents-updated-data-from-ongoing-phase-1-2-solara-trial-demonstrating-encouraging-anti-tumor-activity-of-omni-egfr-inhibitor-bh-30643-in-egfr-c797s-posit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664285564","title":"Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2664285564","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664285564?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:24","pubTimestamp":1788261848,"startTime":"0","endTime":"0","summary":"Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664537848","title":"BlossomHill Therapeutics to Present Updated Phase 1/2 Solara Trial Data on BH-30643 in EGFR-Mutant NSCLC at WCLC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2664537848","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664537848?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:03","pubTimestamp":1788260634,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics to present updated Phase 1/2 SOLARA trial data on BH-30643 in EGFR-mutant NSCLC at WCLC 2026BlossomHill flagged updated Phase 1/2 SOLARA data for BH-30643 in EGFR-mutant NSCLC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL406lNH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","NDAQ","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","BK4585","SG9999014005.SGD","LU2095319765.USD","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","BK4007","BCDF","SG9999014013.SGD","LU2210149790.SGD","BK4112","BK4588","SG9999014039.USD","BLSM","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2W23.USD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664853002","title":"BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664853002","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664853002?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:00","pubTimestamp":1788260400,"startTime":"0","endTime":"0","summary":"Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S BH-30643 was recently granted Fast Tra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3353953/0/en/blossomhill-therapeutics-to-present-updated-data-from-ongoing-phase-1-2-solara-trial-of-its-macrocyclic-omni-egfr-inhibitor-bh-30643-in-egfr-mutant-nsclc-at-the-2026-world-conferen.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664853384","title":"BlossomHill Therapeutics Price Target Announced at $35.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2664853384","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664853384?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:42","pubTimestamp":1788259320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLSM/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664538998","title":"BlossomHill Therapeutics initiated with an Outperform at LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2664538998","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664538998?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:20","pubTimestamp":1788258014,"startTime":"0","endTime":"0","summary":"LifeSci Capital initiated coverage of BlossomHill Therapeutics (BLSM) with an Outperform rating and $32 price target Published first on TheFly – th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-initiated-with-an-outperform-at-lifesci-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-initiated-with-an-outperform-at-lifesci-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664585863","title":"BlossomHill Therapeutics initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2664585863","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664585863?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:15","pubTimestamp":1788257708,"startTime":"0","endTime":"0","summary":"Guggenheim initiated coverage of BlossomHill Therapeutics (BLSM) with a Buy rating and $30 price target Published first on TheFly – the ultimate so...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664079830","title":"Blossomhill Therapeutics, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2664079830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664079830?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:09","pubTimestamp":1788257370,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nAZN4THM76:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664830860","title":"BlossomHill Therapeutics initiated with an Overweight at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2664830860","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664830860?lang=en_us&edition=fundamental","pubTime":"2026-09-01 17:30","pubTimestamp":1788255015,"startTime":"0","endTime":"0","summary":"JPMorgan initiated coverage of BlossomHill Therapeutics (BLSM) with an Overweight rating and $28 price target BlossomHill is a clinical-stage oncol...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-initiated-with-an-overweight-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-initiated-with-an-overweight-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSM","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664836727","title":"U.S. Research Roundup-Autodesk, Hubspot, Oracle","url":"https://stock-news.laohu8.com/highlight/detail?id=2664836727","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664836727?lang=en_us&edition=fundamental","pubTime":"2026-09-01 15:06","pubTimestamp":1788246377,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Autodesk, Hubspot, OracleSept 1 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autodesk, Hubspot an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4N44T0K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSCO","ASMB","BKNU","EGP","ANET","CSR","CPT","AMAT","DUOL","ANNX","BBIO","DASX","ADBE","A","COHR","CSCS","BWA","DBI","DHR","CTRE","ADSK","SAAPLmain","BXSL","VGT","CLOD","CDP","VT","CRWD","TXG","DK","BXP","DRI","BILL","WNDR","ARCC","ACRS","BAH","DASH","ATEN","CAPR","WLDR","BKNG","RDVI","BLSM","CR","ABNB","AAPL","DELL","AKAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664722880","title":"Blossomhill Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Target Price $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2664722880","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664722880?lang=en_us&edition=fundamental","pubTime":"2026-09-01 12:17","pubTimestamp":1788236270,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nFWN44S0QQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660609344","title":"Sector Update: Healthcare Stocks Flat to Higher Premarket Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2660609344","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660609344?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:17","pubTimestamp":1787059061,"startTime":"0","endTime":"0","summary":"Health care stocks were flat to higher premarket Tuesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.7%.Amylyx Pharm","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XBI","AMLX","BLSM","LU0128526141.USD","BK4137","BK4588","IMTX","BK4139","BK4007","LU0029874061.USD","HCSG","XLV","LABU","BK4581","BK4585","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660446439","title":"BlossomHill Says BH-30643 Gets FDA Fast Track Designation in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660446439","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660446439?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:30","pubTimestamp":1787052613,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics (BLSM) said Tuesday the US Food and Drug Administration has granted fast track designation for BH-30643 in advanced or metastatic epidermal growth factor receptor C797S-positi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLSM","BK4588","BK4585","LABU","BK4209","BH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461071","title":"BlossomHill Therapeutics receives fast track designation for BH-30643 from FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461071?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:10","pubTimestamp":1787051413,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics (BLSM) announced that the FDA has granted fast track designation to BH-30643 for the treatment of adult patients with adva...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-receives-fast-track-designation-for-bh-30643-from-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-receives-fast-track-designation-for-bh-30643-from-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BH","BK4139","LABU","BK4588","BK4209","BK4585","BLSM","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461682","title":"Blossomhill Therapeutics Announces FDA Fast Track Designation for Bh-30643, a Macrocyclic Omni-Egfr™ Inhibitor for the Treatment of Advanced Egfr C797s-Positive Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461682?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:00","pubTimestamp":1787050800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nTUACDWHCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31,"code":"91000000","status":"200"}]}}